Back to Gene
RARS2 gene
Reviewed by Medicinsk Expert•Last updated: 2026-10-22•Gene

RARS2 gene

The RARS2 gene encodes a mitochondrial enzyme essential for protein production, and mutations in this gene are linked to severe developmental disorders like pontocerebellar hypoplasia.

Normal Function

The RARS2 gene provides instructions for making an enzyme called mitochondrial arginyl-tRNA synthetase. This enzyme is active in cell structures called mitochondria, which convert the energy from food into a form that cells can use.

Mitochondrial arginyl-tRNA synthetase interacts with a molecule called transfer RNA (tRNA). This molecule helps assemble protein building blocks called amino acids into functioning proteins. Specifically, this enzyme links the amino acid arginine to the tRNA molecule, which then incorporates it into new proteins in mitochondria.

Health Conditions Related to Genetic Changes

Pontocerebellar hypoplasia

At least 13 mutations in the RARS2 gene have been identified in people with a disorder of brain development called pontocerebellar hypoplasia. The major features of this condition include delayed development, problems with movement, and intellectual disability.

  • Most known RARS2 mutations cause pontocerebellar hypoplasia type 6 (PCH6).
  • One mutation has been found in an individual with features of pontocerebellar hypoplasia type 1 (PCH1).

Mutations in this gene significantly reduce or eliminate the function of mitochondrial arginyl-tRNA synthetase, which likely disrupts the production of new proteins in mitochondria.

Other Names for This Gene

  • arginine-tRNA ligase
  • arginyl-tRNA synthetase 2, mitochondrial precursor
  • arginyl-tRNA synthetase-like
  • ArgRS
  • DALRD2
  • dJ382I10.6
  • MGC14993
  • MGC23778
  • PRO1992
  • RARSL
  • SYRM_HUMAN

Genomic Location

The RARS2 gene is found on chromosome 6.

Frequently Asked Questions

clinical geneticist will usually order a targeted gene panel for pontocerebellar hypoplasia or a whole‑exome sequencing test. If a pathogenic RARS2 variant is found, Sanger sequencing of the parents can determine carrier status and inheritance pattern.
There is no cure, but multidisciplinary care can help. Physical and occupational therapy address motor delays, speech therapy supports communication, and anti‑seizure medications are used if seizures occur. Nutritional support and regular monitoring of respiratory function are also important.
Prenatal diagnosis is possible if the family’s specific RARS2 mutation is known. Options include chorionic villus sampling (10‑12 weeks) or amniocentesis (15‑18 weeks) with targeted molecular testing. Ultrasound may show reduced cerebellar size, but genetic testing provides definitive confirmation.
RARS2 disease follows an autosomal‑recessive pattern. If both parents carry one pathogenic copy, each pregnancy has a 25 % chance of an affected child, a 50 % chance of a carrier, and a 25 % chance of having a child without the mutation. Genetic counseling and options such as pre‑implantation genetic testing can be discussed.
Source: MedlinePlus, National Library of Medicine

MedlinePlus brings together authoritative health information from the National Library of Medicine (NLM), the National Institutes of Health (NIH), and other government agencies and health-related organizations.

Meyahealth

Ⓒ 2026. All rights reserved by MEYA